GB0116860D0 - Gel compositions - Google Patents

Gel compositions

Info

Publication number
GB0116860D0
GB0116860D0 GBGB0116860.8A GB0116860A GB0116860D0 GB 0116860 D0 GB0116860 D0 GB 0116860D0 GB 0116860 A GB0116860 A GB 0116860A GB 0116860 D0 GB0116860 D0 GB 0116860D0
Authority
GB
United Kingdom
Prior art keywords
gel
analyte
moieties
sol
entities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0116860.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
De Montfort University
Original Assignee
De Montfort University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by De Montfort University filed Critical De Montfort University
Priority to GBGB0116860.8A priority Critical patent/GB0116860D0/en
Publication of GB0116860D0 publication Critical patent/GB0116860D0/en
Priority to AT02745605T priority patent/ATE513214T1/de
Priority to JP2003512710A priority patent/JP2004534103A/ja
Priority to US10/483,313 priority patent/US8247391B2/en
Priority to PCT/GB2002/003183 priority patent/WO2003006993A2/en
Priority to ES02745605T priority patent/ES2368036T3/es
Priority to DK02745605.2T priority patent/DK1407267T3/da
Priority to PT02745605T priority patent/PT1407267E/pt
Priority to EP02745605A priority patent/EP1407267B1/en
Priority to JP2011058397A priority patent/JP5405511B2/ja
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G01N33/559—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody through a gel, e.g. Ouchterlony technique
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/548—Carbohydrates, e.g. dextran
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Colloid Chemistry (AREA)
GBGB0116860.8A 2001-07-10 2001-07-10 Gel compositions Ceased GB0116860D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB0116860.8A GB0116860D0 (en) 2001-07-10 2001-07-10 Gel compositions
EP02745605A EP1407267B1 (en) 2001-07-10 2002-07-10 Gel compositions
PCT/GB2002/003183 WO2003006993A2 (en) 2001-07-10 2002-07-10 Gel compositions
JP2003512710A JP2004534103A (ja) 2001-07-10 2002-07-10 ゲル組成物
US10/483,313 US8247391B2 (en) 2001-07-10 2002-07-10 Gel compositions
AT02745605T ATE513214T1 (de) 2001-07-10 2002-07-10 Gelzusammensetzungen
ES02745605T ES2368036T3 (es) 2001-07-10 2002-07-10 Composiciones de gel.
DK02745605.2T DK1407267T3 (da) 2001-07-10 2002-07-10 Gelsammensætninger
PT02745605T PT1407267E (pt) 2001-07-10 2002-07-10 Composições de gel
JP2011058397A JP5405511B2 (ja) 2001-07-10 2011-03-16 ゲル組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0116860.8A GB0116860D0 (en) 2001-07-10 2001-07-10 Gel compositions

Publications (1)

Publication Number Publication Date
GB0116860D0 true GB0116860D0 (en) 2001-09-05

Family

ID=9918254

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0116860.8A Ceased GB0116860D0 (en) 2001-07-10 2001-07-10 Gel compositions

Country Status (9)

Country Link
US (1) US8247391B2 (enExample)
EP (1) EP1407267B1 (enExample)
JP (2) JP2004534103A (enExample)
AT (1) ATE513214T1 (enExample)
DK (1) DK1407267T3 (enExample)
ES (1) ES2368036T3 (enExample)
GB (1) GB0116860D0 (enExample)
PT (1) PT1407267E (enExample)
WO (1) WO2003006993A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0116860D0 (en) 2001-07-10 2001-09-05 Univ Montfort Gel compositions
DE10254636A1 (de) * 2002-11-22 2004-06-09 Capsulution Nanoscience Ag Verfahren zum Modifizieren von Mikropartikeln sowie Vorrichtung zum Modifizieren von Mikropartikeln
CA3066594A1 (en) * 2004-10-08 2006-04-20 Georgia Tech Research Corporation Microencapsulation of cells in hydrogels using electrostatic potentials
CN102325814B (zh) * 2009-01-14 2014-03-12 康奈尔大学 用于生物医学用途的生物可降解型水凝胶的制备
CN101745114B (zh) * 2009-12-25 2013-01-23 浙江工业大学 一种对葡萄糖敏感可自控释胰岛素的生物材料的制备方法
US20140350370A1 (en) * 2013-04-08 2014-11-27 The Texas A&M University System Glucose sensing assay
GB201310185D0 (en) 2013-06-07 2013-07-24 Univ Montfort Container
GB201314640D0 (en) * 2013-08-15 2013-10-02 Univ Montfort Matrix gel
CN113350489A (zh) 2015-04-21 2021-09-07 北卡罗来纳州立大学 使用缺氧敏感性纳米复合材料的葡萄糖响应性胰岛素递送系统
CN108366960B (zh) * 2015-10-23 2022-04-19 国立大学法人东京医科齿科大学 药物递送装置
WO2018085809A1 (en) 2016-11-07 2018-05-11 North Carolina State University Patch loaded with dual-sensitive vesicles for enhanced glucose-responsive insulin delivery
NO343313B1 (en) * 2017-03-15 2019-01-28 Lifecare As Fluid composition, method for preparing the composition and use
BR112021011103A8 (pt) * 2018-12-18 2022-08-09 Currahee Holding Company Inc Emplastro personalizado para aplicação tópica
US20220370493A1 (en) * 2019-06-04 2022-11-24 Thirty Holdings Limited Methods and compositions for generating nitric oxide and uses thereof
AU2020286987B2 (en) * 2019-06-04 2025-09-11 Thirty Respiratory Limited Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract
TWI899548B (zh) * 2023-03-13 2025-10-01 羅怡情 染髮用凝膠的用途及製法
CN121243060B (zh) * 2025-11-07 2026-08-11 江苏知原药业股份有限公司 一种高稳定性的阿达帕林凝胶的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705503A (en) * 1986-02-03 1987-11-10 Regents Of The University Of Minnesota Metabolite sensor including a chemical concentration sensitive flow controller for a drug delivery system
GB9200638D0 (en) 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
DE4203466A1 (de) 1992-02-04 1993-08-05 Rudolf Prof Dr Ehwald Affinitaets-sensor
GB9313484D0 (en) * 1993-06-30 1993-08-11 Univ Montfort Drug system ii
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
JP3536186B2 (ja) * 1995-02-27 2004-06-07 独立行政法人 科学技術振興機構 生体内分解性高分子ヒドロゲル
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
WO1998022097A2 (en) * 1996-11-20 1998-05-28 Bio Advances, Llc Controlled release matrix composition using polar polymer or monomer and poly(acrylic acid) blend
GB9805896D0 (en) 1998-03-20 1998-05-13 Eglise David Remote analysis system
CA2337667C (en) 1998-08-10 2008-04-29 Amgen Inc. Dextran-leptin conjugates, pharmaceutical compositions and related methods
AU6931500A (en) 1999-08-27 2001-03-26 M-Biotech, Inc. Glucose biosensor
GB0116860D0 (en) 2001-07-10 2001-09-05 Univ Montfort Gel compositions

Also Published As

Publication number Publication date
ATE513214T1 (de) 2011-07-15
PT1407267E (pt) 2011-09-19
EP1407267A2 (en) 2004-04-14
WO2003006993A2 (en) 2003-01-23
JP2004534103A (ja) 2004-11-11
US8247391B2 (en) 2012-08-21
US20040265386A1 (en) 2004-12-30
WO2003006993A3 (en) 2003-09-25
JP5405511B2 (ja) 2014-02-05
EP1407267B1 (en) 2011-06-15
JP2011144197A (ja) 2011-07-28
ES2368036T3 (es) 2011-11-11
DK1407267T3 (da) 2011-09-19

Similar Documents

Publication Publication Date Title
PT1407267E (pt) Composições de gel
ATE295736T1 (de) Verwendung von interleukin-15
TR200102029T2 (tr) 1-Heterosiklil ikameli diarilaminler.
WO2005058283A3 (en) Stabilised compositions of factor vii polypeptides
GB9909308D0 (en) Measurement and use of molecular interactions
DE50306232D1 (de) Ampholytisches copolymer und dessen verwendung
AU2002238052A1 (en) Antibodies that bind both bcma and taci
ATE412432T1 (de) Internalisierende erbb2 antikörper
TR200102401T2 (tr) C-21 Değiştirilmiş epotilonlar.
MXPA03008957A (es) Modulacion de interacciones de pd-1 con sus ligandos.
BR0200472B1 (pt) composiÇço de fluido de hidrocarboneto lÍquido em forma de gel, e, agente de formaÇço de gel de lÍquido de hidrocarboneto.
DE60115217D1 (de) Alprazolam inklusion-komplexe und ihre pharmazeutischen zusammensetzungen
EP0724456A4 (en) ANTIBODIES AGAINST CD40
ATE251891T1 (de) Verflüssigbare pulverzusammensetzungen
ATE343378T1 (de) Biologisch abbaubares alginatgel mit verzögerter freisetzung
IL151313A0 (en) Lipase containing pharmaceutical compositions
AU1628100A (en) Bidirectional lateral flow test strip and method
DE60010761D1 (de) Initiator/amidine komplexe, solche komplexe enthaltende systeme, und damit hergestellte polymerisierte zusammensetzungen
ATE319416T1 (de) Puderzusammensetzungen
AU6011701A (en) Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same
NO995591L (no) Geler med forsinket, langvarig frigjörelse
AU2001233027A1 (en) Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
WO2003016428A3 (en) Triboluminescent materials and devices containing them
AU2002354205A1 (en) Formulation comprising an ionic compound, a polyionic polymer, a nd a copolymer.
DK1147068T3 (da) Fast sammensætning, der indeholder faste partikler og bindemiddel

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)